Molecular imaging in prostate cancer can play the additional critical role of an early biomarker for response to therapy, similar to how 18F-FDG is used in other malignancies.
Akiva Mintz, MD, PhD, MHA
Advertisement
Articles by Akiva Mintz, MD, PhD, MHA
Advertisement
Latest Updated Articles
- PET/CT in Prostate Cancer: An Unmet Clinical Need
Published: December 15th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
2
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
3
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
4
Career Stage and Location Found to Impact Oncology Coverage in the US
5
